Marina Montagnani Marelli

List of Publications by Year
in descending order

57 papers	2,087 citations	218677 26 h-index	233421 45 g-index
58 all docs	58 docs citations	58 times ranked	2545 citing authors

#	Article	IF	Citations
1	The Role of HSPB8, a Component of the Chaperone-Assisted Selective Autophagy Machinery, in Cancer. Cells, 2021, 10, 335.	4.1	28
2	Apoptosis-mediated anticancer activity in prostate cancer cells of a chestnut honey (Castanea sativa) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	2.7	12
3	Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions. International Journal of Molecular Sciences, 2020, 21, 9511.	4.1	23
4	Anticancer properties of tocotrienols: A review of cellular mechanisms and molecular targets. Journal of Cellular Physiology, 2019, 234, 1147-1164.	4.1	45
5	Cellular and molecular biology of cancer stem cells in melanoma: Possible therapeutic implications. Seminars in Cancer Biology, 2019, 59, 221-235.	9.6	39
6	Unraveling the molecular mechanisms and the potential chemopreventive/therapeutic properties of natural compounds in melanoma. Seminars in Cancer Biology, 2019, 59, 266-282.	9.6	23
7	Role of Endoplasmic Reticulum Stress in the Anticancer Activity of Natural Compounds. International Journal of Molecular Sciences, 2019, 20, 961.	4.1	93
8	Tocotrienols and Cancer: From the State of the Art to Promising Novel Patents. Recent Patents on Anti-Cancer Drug Discovery, 2019, 14, 5-18.	1.6	19
9	Î´â€Tocotrienol induces apoptosis, involving endoplasmic reticulum stress and autophagy, and paraptosis in prostate cancer cells. Cell Proliferation, 2019, 52, e12576.	5.3	69
10	Targeting melanoma stem cells with the Vitamin E derivative Î´-tocotrienol. Scientific Reports, 2018, 8, 587.	3.3	46
11	Semi-preparative HPLC purification of Î´-tocotrienol (Î´-T3) from <i>Elaeis guineensis</i> Jacq. and <i>Bixa orellana</i> L. and evaluation of its <i>in vitro</i> anticancer activity in human A375 melanoma cells. Natural Product Research, 2018, 32, 1130-1135.	1.8	24
12	Dual role of autophagy on docetaxel-sensitivity in prostate cancer cells. Cell Death and Disease, 2018, 9, 889.	6.3	82
13	GnRH in the Human Female Reproductive Axis. Vitamins and Hormones, 2018, 107, 27-66.	1.7	39
14	Estrogen Receptor Î² in Melanoma: From Molecular Insights to Potential Clinical Utility. Frontiers in Endocrinology, 2016, 7, 140.	3.5	57
15	Vitamin E Î´-tocotrienol triggers endoplasmic reticulum stress-mediated apoptosis in human melanoma cells. Scientific Reports, 2016, 6, 30502.	3.3	56
16	GnRH and GnRH receptors in the pathophysiology of the human female reproductive system. Human Reproduction Update, 2016, 22, 358-381.	10.8	156
17	Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor. International Journal of Oncology, 2015, 46, 243-253.	3.3	16
18	Estrogen Receptor Î² Agonists Differentially Affect the Growth of Human Melanoma Cell Lines. PLoS ONE, 2015, 10, e0134396.	2.5	38

#	Article	IF	Citations
19	FROM EMERGING BIOLOGICAL INSIGHTS TO NOVEL TREATMENT STRATEGIES IN PROSTATE CANCER. Istituto Lombardo - Accademia Di Scienze E Lettere - Rendiconti Di Scienze, 2014, , .	0.0	0
20	Gonadotropin-Releasing Hormone Agonists Sensitize, and Resensitize, Prostate Cancer Cells to Docetaxel in a p53-Dependent Manner. PLoS ONE, 2014, 9, e93713.	2.5	14
21	<i>In Vitro</i>Chronic Administration of ERbeta Selective Ligands and Prostate Cancer Cell Growth: Hypotheses on the Selective Role of 3beta-Adiol in AR-Positive RV1 Cells. BioMed Research International, 2014, 2014, 1-14.	1.9	7
22	Targeting Hormonal Signaling Pathways in Castration Resistant Prostate Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2014, 9, 267-285.	1.6	10
23	GnRH Receptors in Cancer: From Cell Biology to Novel Targeted Therapeutic Strategies. Endocrine Reviews, 2012, 33, 784-811.	20.1	137
24	Molecular mechanisms of the antimetastatic activity of nuclear clusterin in prostate cancer cells. International Journal of Oncology, 2011, 39, 225-34.	3.3	8
25	Evaluation of a Stable Gonadotropin-Releasing Hormone Analog in Mice for the Treatment of Endocrine Disorders and Prostate Cancer. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 613-623.	2.5	17
26	Dual Targeting of Tumor and Endothelial Cells by Gonadotropin-Releasing Hormone Agonists to Reduce Melanoma Angiogenesis. Endocrinology, 2010, 151, 4643-4653.	2.8	15
27	Type I Gonadotropin-Releasing Hormone Receptor Mediates the Antiproliferative Effects of GnRH-II on Prostate Cancer Cells. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1761-1767.	3.6	36
28	Novel insights into GnRH receptor activity: Role in the control of human glioblastoma cell proliferation. Oncology Reports, 2009, 21, 1277-82.	2.6	18
29	Clusterin Isoforms Differentially Affect Growth and Motility of Prostate Cells: Possible Implications in Prostate Tumorigenesis. Cancer Research, 2007, 67, 10325-10333.	0.9	53
30	Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. International Journal of Oncology, 2007, 30, 261.	3.3	6
31	Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. International Journal of Oncology, 2007, 30, 261-71.	3.3	4
32	Gonadotropin-Releasing Hormone (GnRH) Receptors in Tumors: a New Rationale for the Therapeutical Application of GnRH Analogs in Cancer Patients?. Current Cancer Drug Targets, 2006, 6, 257-269.	1.6	54
33	Insulin-like growth factor-I promotes migration in human androgen-independent prostate cancer cells via the alphavbeta3 integrin and PI3-K/Akt signaling. International Journal of Oncology, 2006, 28, 723-30.	3.3	20
34	Activation of the orphan nuclear receptor RORÎ± counteracts the proliferative effect of fatty acids on prostate cancer cells: Crucial role of 5-lipoxygenase. International Journal of Cancer, 2004, 112, 87-93.	5.1	45
35	The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. Frontiers in Neuroendocrinology, 2003, 24, 279-295.	5.2	114
36	Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression.. Endocrine-Related Cancer, 2003, 10, 161-167.	3.1	35

#	Article	IF	Citations
37	Locally Expressed LHRH Receptors Mediate the Oncostatic and Antimetastatic Activity of LHRH Agonists on Melanoma Cells. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3791-3797.	3.6	53
38	Locally Expressed LHRH Receptors Mediate the Oncostatic and Antimetastatic Activity of LHRH Agonists on Melanoma Cells. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3791-3797.	3.6	14
39	Oncostatic activity of a thiazolidinedione derivative on human androgen-dependent prostate cancer cells. International Journal of Cancer, 2001, 92, 733-737.	5.1	20
40	Activation of the orphan nuclear receptor ROR? induces growth arrest in androgen-independent DU 145 prostate cancer cells. Prostate, 2001, 46, 327-335.	2.3	25
41	LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opinion on Investigational Drugs, 2001, 10, 709-720.	4.1	90
42	Growth-inhibitory activity of melatonin on human androgen-independent DU 145 prostate cancer cells. Prostate, 2000, 45, 238-244.	2.3	69
43	The Luteinizing Hormone-Releasing Hormone Receptor in Human Prostate Cancer Cells: Messenger Ribonucleic Acid Expression, Molecular Size, and Signal Transduction Pathway1. Endocrinology, 1999, 140, 5250-5256.	2.8	123
44	Luteinizing Hormone-Releasing Hormone Agonists Interfere with the Mitogenic Activity of the Insulin-Like Growth Factor System in Androgen-Independent Prostate Cancer Cells. Endocrinology, 1999, 140, 329-334.	2.8	16
45	The Luteinizing Hormone-Releasing Hormone Receptor in Human Prostate Cancer Cells: Messenger Ribonucleic Acid Expression, Molecular Size, and Signal Transduction Pathway. Endocrinology, 1999, 140, 5250-5256.	2.8	30
46	Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. International Journal of Cancer, 1998, 76, 506-511.	5.1	42
47	Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth. Journal of Steroid Biochemistry and Molecular Biology, 1996, 56, 107-111.	2.5	28
48	Growth factors in steroid-responsive prostatic tumor cells. Steroids, 1996, 61, 222-225.	1.8	7
49	LHRH as a growth-inhibitory factor in prostatic tumor cells: possible mechanism of action. Endocrine-Related Cancer, 1996, 3, 211-216.	3.1	2
50	Luteinizing hormone-releasing hormone agonists interfere with the stimulatory actions of epidermal growth factor in human prostatic cancer cell lines, LNCaP and DU 145. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 3930-3937.	3.6	57
51	LH-RH and Somatostatin: Examples of Peptidergic Control of Prostate Cancer Growth. Contributions To Oncology / Beitrage Zur Onkologie, 1995, 50, 332-344.	0.1	0
52	HUMAN PROSTATIC-CARCINOMA CELL-LINE LNCAP DEGRADES LUTEINIZING-HORMONE-RELEASING HORMONE. International Journal of Oncology, 1995, 6, 1231-6.	3.3	2
53	Growth of the androgen-dependent tumor of the prostate: Role of androgens and of locally expressed growth modulatory factors. Journal of Steroid Biochemistry and Molecular Biology, 1995, 53, 401-405.	2.5	20
54	Androgen-dependent prostatic tumors: biosynthesis and possible actions of LHRH. Journal of Steroid Biochemistry and Molecular Biology, 1994, 49, 347-350.	2.5	15

#	Article	IF	Citations
55	Characterization of a soluble LHRH-degrading activity in the rat ventral prostate. Prostate, 1993, 23, 315-328.	2.3	9
56	Gonadotropin-releasing hormone agonists suppress melanoma cell motility and invasiveness through the inhibition of Î±3 integrin and MMP-2 expression and activity. International Journal of Oncology, 1992, 33, 405.	3.3	7
57	REPRODUCTIVE FUNCTION AND ANTITUMOR ACTIVITY: DIFFERENT ROLES FOR THE HYPOTHALAMIC HORMONE GnRH. Istituto Lombardo - Accademia Di Scienze E Lettere - Incontri Di Studio, 0, , .	0.0	0